uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results

uniQure N.V. (NASDAQ:QURE) is one of the 12 Best Performing Stocks in the Last 3 Months. On October 8, RBC Capital reiterated a Buy rating on uniQure N.V. (NASDAQ:QURE) and increased its price target from $55 to $65.

Moreover, on October 6, H.C. Wainwright also raised its price target on uniQure N.V. (NASDAQ:QURE) from $70 to $110 and kept a Buy rating.

uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results

These updates came after the company reported positive topline data from its Phase I/II study of AMT-130 for treating Huntington’s disease on September 24. The data showed that its gene therapy, AMT-130, slowed down the progression of Huntington’s disease.

According to the report, this pivotal study met the primary endpoint and showed that a high dose of AMT-130 slowed the disease by 75% over 36 months. uniQure N.V. (NASDAQ:QURE) also said that the treatment was generally safe and well-tolerated.

Currently, there are no approved therapies to delay the onset or slow the progression of Huntington’s disease. uniQure N.V.’s (NASDAQ:QURE) AMT-130 could significantly change the treatment landscape for this disease

The FDA has granted AMT-130 a special designation as a Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT). uniQure N.V. (NASDAQ:QURE) expects to submit a biologics license application (BLA) in the first quarter of 2026 and plans to launch the treatment in the US later that year after approvals.

uniQure N.V. (NASDAQ:QURE) is a Dutch biotechnology company focused on developing gene therapies for serious diseases.

READ NEXT: 10 Best American AI Stocks to Buy According to Analysts and 11 Dirt Cheap Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.